The block of hematopoietic differentiation program in acute myeloid leukemia cells can be overcome by differentiating agent like retinoic acid, but it has several side effects. A study of other differentiation signaling pathways is therefore useful to predict potential targets of anti-leukemic therapy. We demonstrated previously that the co-treatment of HL-60 cells with Tumor necrosis factor-alpha (TNF-alpha) (1 ng/mL) and inhibitor of 5-lipoxygenase MK886 (5 microm) potentiated both monocytic differentiation and apoptosis. In this study, we detected enhanced activation of three main types of mitogen-activated protein kinases (MAPKs) (p38, c-Jun amino-terminal kinase [JNK], extracellular signal-regulated kinase [ERK]), so we assessed their role in differentiation using appropriate pharmacologic inhibitors. The inhibition of pro-apoptotic MAPKs (p38 and JNK) suppressed the effect of MK886 + TNF-alpha co-treatment. On the other hand, down-regulation of pro-survival ERK pathway led to increased differentiation. Those effects were accompanied by increased activation of caspases in cells treated by MK886 + TNF-alpha. Pan-caspase inhibitor ZVAD-fmk significantly decreased both number of apoptotic and differentiated cells. The same effect was observed after inhibition of caspase 9, but not caspase 3 and 8. To conclude, we evidenced that the activation of apoptotic processes and pathways supporting apoptosis (p38 and JNK MAPKs) is required for the monocytic differentiation of HL-60 cells.

Department of Cytokinetics Institute of Biophysics Academy of Sciences of Czech Republic vvi Brno Czech Republic

000      

03625naa 2200493 a 4500

001      

bmc11016849

003      

CZ-PrNML

005      

20121122122600.0

008      

110628s2009 xxk e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Medalová, Jiřina $7 xx0102053

245    10

$a Monocytic differentiation of leukemic HL-60 cells induced by co-treatment with TNF-alpha and MK886 requires activation of pro-apoptotic machinery / $c J. Procházková, L. Stixová, K. Souček, J. Hofmanová, A. Kozubík

314    __

$a Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of Czech Republic, vvi, Brno, Czech Republic.

520    9_

$a The block of hematopoietic differentiation program in acute myeloid leukemia cells can be overcome by differentiating agent like retinoic acid, but it has several side effects. A study of other differentiation signaling pathways is therefore useful to predict potential targets of anti-leukemic therapy. We demonstrated previously that the co-treatment of HL-60 cells with Tumor necrosis factor-alpha (TNF-alpha) (1 ng/mL) and inhibitor of 5-lipoxygenase MK886 (5 microm) potentiated both monocytic differentiation and apoptosis. In this study, we detected enhanced activation of three main types of mitogen-activated protein kinases (MAPKs) (p38, c-Jun amino-terminal kinase [JNK], extracellular signal-regulated kinase [ERK]), so we assessed their role in differentiation using appropriate pharmacologic inhibitors. The inhibition of pro-apoptotic MAPKs (p38 and JNK) suppressed the effect of MK886 + TNF-alpha co-treatment. On the other hand, down-regulation of pro-survival ERK pathway led to increased differentiation. Those effects were accompanied by increased activation of caspases in cells treated by MK886 + TNF-alpha. Pan-caspase inhibitor ZVAD-fmk significantly decreased both number of apoptotic and differentiated cells. The same effect was observed after inhibition of caspase 9, but not caspase 3 and 8. To conclude, we evidenced that the activation of apoptotic processes and pathways supporting apoptosis (p38 and JNK MAPKs) is required for the monocytic differentiation of HL-60 cells.

590    __

$a bohemika - dle Pubmed

650    _2

$a chloromethylketony aminokyselin $x farmakologie $7 D000590

650    _2

$a apoptóza $x fyziologie $x účinky léků $7 D017209

650    _2

$a kaspasy $x antagonisté a inhibitory $x metabolismus $7 D020169

650    _2

$a buněčná diferenciace $x účinky léků $7 D002454

650    _2

$a inhibitory cysteinových proteinas $x farmakologie $7 D015853

650    _2

$a aktivace enzymů $x účinky léků $7 D004789

650    _2

$a HL-60 buňky $7 D018922

650    _2

$a lidé $7 D006801

650    _2

$a indoly $x farmakologie $7 D007211

650    _2

$a akutní promyelocytární leukemie $x farmakoterapie $x metabolismus $x patologie $7 D015473

650    _2

$a inhibitory lipoxygenas $x farmakologie $7 D016859

650    _2

$a MAP kinasový signální systém $x účinky léků $7 D020935

650    _2

$a monocyty $x patologie $x účinky léků $7 D009000

650    _2

$a NF-kappa B $x antagonisté a inhibitory $7 D016328

650    _2

$a TNF-alfa $x farmakologie $7 D014409

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Stixová, Lenka $7 xx0142378

700    1_

$a Souček, Karel $7 xx0140754

700    1_

$a Hofmanová, Jiřina, $d 1950- $7 xx0074130

700    1_

$a Kozubík, Alois, $d 1958- $7 mzk2004237023

773    0_

$t European Journal of Haematology $w MED00001620 $g Roč. 83, č. 1 (2009), s. 35-47

910    __

$a ABA008 $b x $y 2

990    __

$a 20110720122253 $b ABA008

991    __

$a 20121122122623 $b ABA008

999    __

$a ok $b bmc $g 864095 $s 726641

BAS    __

$a 3

BMC    __

$a 2009 $x MED00001620 $b 83 $c 1 $d 35-47 $m European journal of haematology $n Eur J Haematol

LZP    __

$a 2011-3B09/BBjvme